Tag: food

Artists Including Spoon, Gary Clark Jr., Ziggy Marley, STS9, Mike Campbell & The Dirty Knobs, De La Soul, Broken Social Scene, JJ Grey &...

Novo Nordisk's Wegovy® pill has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity for adults

2026 Industry Health Survey Highlights Strong Consumer Demand, Significant Economic Impact, and Industry InnovationAUSTIN, Texas, June 11, 2026 /PRNewswire/ -- The rent-to-own (RTO) industry...

Cosmos Health secures additional 180-day Nasdaq extension to regain compliance.

Mission-aligned ownership and new leadership will increase access to sustainably grown microgreensDANVILLE, Va., June 11, 2026 /PRNewswire/ -- AeroFarms, an indoor vertical farming company and...

60 Degrees Pharma licensed FSU technology for Australian Chestnut Extract production and plans FDA discussions before refiling its NDIN.

FIRST-EVER FDA-CLEARED PERSONALIZED CLINICAL TREATMENT SYSTEM FOR POST-TRAUMATIC STRESS DISORDER (PTSD) ESTABLISHES A NEW CATEGORY IN PRECISION MENTAL HEALTHCARENEWPORT BEACH, Calif., June 11, 2026...

Findings from Phase 2 of the "Power of Play: Family Connection" study from Kinder and the University of East London (UEL) confirm that shared...

Findings from Phase 2 of the "Power of Play: Family Connection" study from Kinder and the University of East London (UEL) confirm that shared...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.